Alan Barge, MD


Alan Barge trained in medicine at Oxford and London, and specialized in hematology and oncology, completing research and clinical fellowships in Seattle in 1990. Alan joined Amgen in 1990, as European Medical Director, and was responsible for the European, and subsequently worldwide development of Neupogen® (filgrastim), and other haemopoietic growth factors. Alan has led FDA BRMAC and EMA/CHMP submissions and presentations for a number of new indications for filgrastim.

In 1999, Alan joined AstraZeneca, where he established a team responsible for early phase oncology drug development. In 2003, Alan was made responsible for the re‐focusing of the development, and registration of Iressa® (gefitinib) in Asia, and Europe, in molecularly defined subsets of NSCLC. He was subsequently appointed VP of Clinical and Head of Oncology and Infection, responsible for building and managing a large development group, and the execution of AstraZeneca’s oncology portfolio globally. In this role, Alan was responsible for re-shaping the discovery and development groups, and for the acquisition of Kudos, which yielded the drug olaparib (Lynparza®).

Alan left AstraZeneca in 2011 and co-founded ASLAN Pharmaceuticals, a Singapore-based biopharmaceutical company which focuses on Asia-prevalent cancers.

In 2016, Alan helped found Carrick Therapeutics in the UK, which also focuses on early-stage oncology assets. Along with the CEO and CSO he raised $95M in a combined Series A/B initial funding round.